



Universiteit
Leiden
The Netherlands

Glycosidases as an analytical tool in glycomics assays

Rebello, O.D.

Citation

Rebello, O. D. (2022, October 13). *Glycosidases as an analytical tool in glycomics assays*. Retrieved from <https://hdl.handle.net/1887/3480319>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3480319>

Note: To cite this publication please use the final published version (if applicable).

Chapter 4

**A matrix assisted laser desorption/ionization
mass spectrometry assay for the relative
quantitation of antennary fucosylated *N*-glycans
in human plasma**

Abstract

Changes in the abundance of antennary fucosylated glycans in human total plasma *N*-glycome (TPNG) have been associated with several diseases ranging from diabetes to various forms of cancer. However, it is challenging to address this important part of the human glycome. Most commonly, time-consuming chromatographic separations are performed to differentially quantify core and antenna fucosylation. Obtaining sufficient resolution for larger, more complex glycans can be challenging. We introduce a matrix-assisted laser desorption/ionization – mass spectrometry (MALDI-MS) assay for the relative quantitation of antennary fucosylation in TPNG. *N*-linked glycans are released from plasma by PNGase F and further treated with a core fucosidase before performing a linkage-informative sialic acid derivatization. The core fucosylated glycans are thus depleted while the remaining antennary fucosylated glycans are quantitated. Simultaneous quantitation of α 2,3-linked sialic acids and antennary fucosylation allows an estimation of the sialyl-Lewis X motif. The approach is feasible using either ultrahigh-resolution Fourier-transform ion cyclotron resonance mass spectrometry or time-of-flight mass spectrometry. The assay was used to investigate changes of antennary fucosylation as clinically relevant marker in 14 colorectal cancer patients. In accordance with a previous report, we found elevated levels of antennary fucosylation pre-surgery which decreased after tumor resection. The assay has the potential for revealing antennary fucosylation signatures in various conditions including diabetes and different types of cancer.

Introduction

Changes in the relative abundance of either core or antennary fucosylation have been associated with certain diseases or disease states [1, 2]. Here, we focus on antennary fucosylation in human total plasma *N*-glycome (TPNG) as a clinically relevant disease marker. For instance, the abundance of antennary fucosylation in TPNG has been correlated with 1) certain cancers such as hepatocellular carcinoma [3, 4], ovarian cancer [5] and colorectal cancer [6-8]; 2) hepatocyte nuclear factor 1 homeobox A - maturity-onset diabetes of the young (HNF1A - MODY) [9, 10]; 3) inflammatory conditions [11, 12] and 4) with attention-deficit hyperactivity disorder in children [13]. These correlations have created a need for the development of assays for quantitation of antennary fucosylation in TPNG. Quantitation of changes in core fucosylated glycans will remain relevant as well, but can be better covered by existing approaches.

The quantitation of antennary fucosylation in TPNG was also used for more specialized clinical purposes such as for prognosis or for differentiating between closely related diseases. For example, a lowered incidence of antennary fucosylation on triantennary glycans was shown to discriminate HNF1A-MODY patients from Type 1 and Type 2 diabetes [10]. Current genetic tests for diagnosing HNF1A-MODY are sometimes inconclusive, and there is a demand for additional diagnostic markers [14-16]. Plasma *N*-glycome antennary fucosylation has been reported to be regulated by HNF1A making it a proxy of HNF1A expression levels and functions [17]. Hence, quantitation of antennary fucosylation in TPNG has been found to be an HNF1A-MODY disease biomarker with potential for complementing genetic tests in disease diagnosis [10, 17]. For colorectal cancer, both better diagnosis and prediction of long-term survival are urgent clinical needs. Currently, long-term survival predictions are mostly based on tumor node metastasis classification which has low success rates [8, 18]. This negatively affects the decision making on therapy given to the patients. Antennary fucosylation was shown to be associated with the recovery of colorectal cancer patients after tumor resection [8], and thus may have the potential for long-term survival prediction.

TPNG is a rich and convenient source of valuable associations with diseases and disease states. It reflects the loss of systemic or cellular homeostasis which may affect the regulation of glycosylation pathways [1, 17, 19]. Enabling a bird's-eye view, TPNG analysis is highly complementary to the target analysis of specific proteins. Quantitation of low abundant antennary fucosylated glycans in human TPNG is complicated by the structural diversity of its component glycans. This diversity is a combination of monosaccharide composition variants and linkage isomers [20, 21]. Composed of diantennary, triantennary and tetraantennary *N*-glycans, TPNG also features bisecting *N*-acetylglucosamine and glycans with *N*-acetylglucosamine repeats, and complexity is added by different levels of galactosylation, sialylation and fucosylation [21-23]. Fucosylation can be classified as either core or antennary (Figure 1). Core fucosylation is linked by an $\alpha(1-6)$ glycosidic bond to the reducing end *N*-acetylglucosamine. Antennary fucosylation in TPNG mainly features fucose residues that are linked by an $\alpha(1-3)$ glycosidic bond (Lewis X epitope) to antennary *N*-acetylglucosamine residues [24].




Figure 1. Fucose epitopes on N-glycans in human plasma. [Blue square: N-acetylglucosamine, green circle: mannose, yellow circle: galactose, red triangle: fucose, pink diamond: N-acetylneuraminic acid (+45° α 2,6-linked; -45° α 2,3-linked). For compositions see Figure 6].

Methods for sample preparation and analysis of human TPNG have been developed on a number of analytical platforms. This includes liquid chromatography (LC) – fluorescence detection (FLD) [6, 13, 20, 25], MALDI-MS [22, 26, 27], and capillary gel electrophoresis – laser-induced fluorescence [28, 29]. Each method has its advantages and disadvantages when it comes to measuring antennary fucosylation. Capillary gel electrophoresis – laser-induced fluorescence [28] and LC-FLD [6, 13] are able to resolve some antennary fucosylated glycans in TPNG along their chromatographic dimension. However, LC-FLD often requires extensive measurement time. Nonetheless, due to its high precision and robustness, one of the most attractive techniques for routine applications is LC-FLD. MALDI-MS is gaining popularity in biomarker analysis since it features short measurement time and high molecular resolution. This, combined with linkage-informative sialic acid derivatization, is the ideal basis for a high throughput TPNG glycomics assay in a research setting [22, 26, 27]. However, due to identical mass, the differentiation between core fucosylation and antennary fucosylation in monofucosylated glycans of the same composition is not achieved by MALDI-MS. Therefore, additional experiments are needed such as tandem mass spectrometry [30-32] or exoglycosidase treatment [20]. Unfortunately, relative quantitation of fucose isomers by tandem MS is hindered by the vastly different efficiencies of the fragmentation pathways [32, 33]. Additionally, potential fucose rearrangement influences the ratios of diagnostic fragment ion(s), further interfering with the assessment of mixtures by tandem MS [30, 31, 34]. Alternatively, endoglycosidases can be used for glycomics assays [4, 35]. For example, a combination of Endo F2 and Endo F3 has been used to quantify antennary fucosylation on diantennary and triantennary glycans on hemopexin and complement factor H in patients suffering from liver diseases [4]. However, until now, this approach has not been demonstrated on TPNG. Due to the narrow specificity of these endoglycosidases in contrast to the vast structural diversity of TPNG, such an approach may not be suitable for TPNG.

We developed an assay for the relative quantitation of antennary fucosylation in human TPNG by combining MALDI-MS and exoglycosidase approaches. It can be viewed as complementing the existing approach for TPNG measurement by MALDI-MS. The assay was applied to 14 colorectal cancer patient samples. Consistent antennary fucosylation changes pre vs. post tumor resection were detected which revealed the assays potential for addressing biomedical research questions.

Materials and Methods

Reagents and samples

Disodium hydrogen phosphate dihydrate, potassium dihydrogen phosphate, sodium chloride, 85% phosphoric acid, 30%-33% (v/v%) ammonium hydroxide, Nonidet P-40 substitute (NP-40), 1-hydroxybenzotriazole 97% (HOBT), ammonium acetate and super-DHB (9:1 mixture of 2,5-dihydroxybenzoic acid and 2-hydroxy-5-methoxybenzoic acid) were purchased from Sigma Aldrich Chemie GmbH (Steinheim, Germany). 1-Ethyl-3-(3-(dimethylamino)propyl)carbodiimide hydrochloride (EDC) was purchased from Fluorochem (Hadfield, UK). Analytical grade ethanol, analytical grade glacial acetic acid, sodium dodecyl sulfate (SDS), trifluoroacetic acid, and potassium hydroxide were purchased from Merck KGaA (Darmstadt, Germany). HPLC-grade acetonitrile was purchased from Biosolve (Valkenswaard, The Netherlands). Girard's Reagent P (GiRP) was purchased from TCI Development Co. Ltd. (Tokyo, Japan). 5x phosphate buffered saline solution (PBS; 175 mM; pH 7.3) was prepared by dissolving 285 g of disodium hydrogen phosphate dihydrate, 23.8 g of potassium dihydrogen phosphate and 425 g of sodium chloride in 10 L deionized water. The 5x acidic PBS was prepared by adding 68 μ L of 85% phosphoric acid (14.7M) to 9.93 mL of the 5x PBS. Recombinant peptide N-glycosidase F (PNGase F) was obtained from Roche Diagnostics (Mannheim, Germany). The recombinant core fucosidase, commercially known as α 1-2,4,6 Fucosidase O, was purchased from New England BioLabs (MA, USA). However, activity on the α 1,4-linkage is reported as very low. Under the employed conditions, the enzyme did not noticeably act on antennary fucoses present in TPNG (see section Result and Discussion). Peptide Calibration Standard II was purchased from Bruker Daltonic (Bremen, Germany).

Human plasma standard (Visucon-F frozen normal control plasma, pooled from a minimum of 20 human donors, citrated and buffered in 0.02M 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) was purchased from Affinity Biologicals (Ancaster, Ontario, Canada).

The pre-operative vs. 45 days post-operative pairs of 14 colorectal cancer patient samples were collected as part of a biobank as was previously described [8]. These serum samples were collected between October 2002 and March 2013 by the Leiden University Medical Center Surgical Oncology Biobank. This study was approved by the Medical Ethics Committee of the Leiden University Medical Center and was performed in accordance with the Code of Conduct of the Federation of Medical Scientific Societies in the Netherlands (<http://www.federa.org/>).

N-glycan release

PNGase F release of human TPNG was performed similarly as previously described [22]. Briefly, 4 μL of plasma was added to 8 μL of 2% SDS in a polypropylene 96 well V-bottom plate (V-96 microwell, NUNC, Roskilde, Denmark). The plate was sealed (adhesive plate seals, Thermo Scientific, UK) and mildly shaken on a plate shaker for 5 minutes, before incubating at 60°C for 10 minutes. Additionally, 8 μL of the PNGase F releasing mixture (4 μL of 4% NP-40 solution, 4 μL of 5x acidic PBS and 0.4 μL of PNGase F) was then added to the plasma samples. The plate was sealed and mildly shaken on a plate shaker for 5 minutes before incubating overnight (15 – 18 hours) at 37°C.

Depletion of core fucosylation

The overnight incubated plasma release mixture (5 μL) was diluted with 45 μL of 1x acidic PBS solution in a 96 well V-bottom plate (V-96 microwell, Greiner Bio-one, Germany). The plate was mildly shaken on a plate shaker for 5 minutes, before transferring 1 μL to 2 μL of core fucosidase mixture (0.65 μL deionized water, 0.75 μL of 4% NP-40 solution, 0.4 μL of 5x acidic PBS and 0.2 μL / 0.4 Units of core fucosidase) in a 96 well V-bottom plate. After sealing of the plate, the samples were incubated overnight (15 – 18 hours) at 37°C in an enclosed, humidified chamber to prevent evaporation.

Linkage specific sialic acid derivatization

Sialic acid derivatization was performed as previously described [23], but with minor alterations. With this approach, the carboxylic acid groups of $\alpha(2,6)$ -linked sialic acids are ethyl esterified while the $\alpha(2,3)$ -linked sialic acids are amidated. Briefly, 60 μL of ethyl esterification reagent (solution of 0.25 M EDC and 0.25 M HOBt in ethanol) was added to the core defucosylated samples. The plate was sealed and incubated at 37°C for 30 minutes. 12 μL of 30%-33% (v/v%) NH_4OH solution were added to the wells and the sealed plate incubated for another 30 minutes at 37°C. 72 μL of acetonitrile was added to the wells, after which cotton hydrophilic interaction liquid chromatography (HILIC) - solid-phase extraction (SPE) microtip purification was performed immediately.

Cotton hydrophilic interaction liquid chromatography - solid-phase extraction microtip purification

This purification step was performed as previously described [36] with minor modifications. The cotton HILIC- SPE microtips were prepared by inserting a cotton strand of length 3 - 4 mm into a 20 μL capacity microtip (Mettler-Toledo, Switzerland) and pushing it into place with a stream of pressurized air/nitrogen. Conditioning was performed by pipetting 5 times 20 μL of water, followed by an equilibration step of pipetting 3 times 20 μL of 85% acetonitrile. The derivatized samples were loaded onto the HILIC-SPE by pipetting 20 μL of it 20 times. Washing was performed with 3 times 20 μL of 85% acetonitrile containing 1% trifluoroacetic acid and 3 times 20 μL of 85% acetonitrile, consecutively. The glycans were eluted from the HILIC-SPE

by repeatedly, 10 times, pipetting 4 μL of deionized water in a 96 well V-bottom plate (V-96 microwell, Greiner Bio-one, Germany). All steps were performed with a 12 channel multi-channel pipette.

Purified glycan samples (1 μL) were spotted on an MTP anchor chip 600/384 TF MALDI target plate (Bruker Daltonics, Bremen, Germany), followed by the addition of 1 μL of the MALDI matrix solution (50% acetonitrile solution of 2.5 mg/mL super-DHB and 0.1 mM sodium hydroxide). The solutions were mixed on the plate with a pipette. The spotted samples were allowed to air dry before performing MALDI- time-of-flight -MS (MALDI-TOF-MS) or MALDI-Fourier-transform ion cyclotron resonance -MS (MALDI-FT-ICR-MS) measurements.

MALDI-TOF-MS analysis

The analysis was performed on an UltrafleXtreme Mass spectrometer in reflectron positive ion mode (Bruker Daltonics, Bremen, Germany) which was operated by FlexControl version 3.4 (Build 135). A Bruker Smartbeam- II laser was used for ionization at an irradiation frequency of 1 kHz using the "small" predefined laser shot pattern. Each sample spot was irradiated by 20,000 shots with 200 shots at each laser raster. Irradiation was performed randomly over the complete sample spot. Spectra were recorded within an m/z range of 900 – 5000. Samples were measured in an automated manner using the AutoXecute function of FlexControl. Before each measurement, the instrument was calibrated with a peptide standard mix (Peptide Calibration Standard II, Bruker Daltonics).

MALDI-FT-ICR-MS analysis

The analysis was performed in positive ion mode on a Bruker 15T solariX XR FT-ICR mass spectrometer equipped with a CombiSource and a ParaCell (Bruker Daltonics). The system was operated by ftmsControl version 2.2.0 (Build 150). A Bruker Smartbeam- II laser was used for ionization at an irradiation frequency of 500 Hz using the "medium" predefined laser shot pattern. Each sample spot was irradiated with a raster of 200 laser shots. 10 such scans were performed randomly over the complete sample spot. Spectra were acquired within an m/z -range 1011–5000 with 1 million data points (transient time 2.3069 s). Samples were measured in an automated manner using the AutoXecute function of ftmsControl.

Processing of MALDI-MS data

The MALDI-TOF-MS spectra were internally calibrated using FlexAnalysis version 3.4 (Build 76; Bruker Daltonic). The glycan calibrants used were $[\text{H3N4} + \text{Na}]^+$ of m/z 1339.476, $[\text{H5N4} + \text{Na}]^+$ of m/z 1663.581, $[\text{H5N4E1} + \text{Na}]^+$ of m/z 1982.708, $[\text{H5N4E2} + \text{Na}]^+$ of m/z 2301.835, $[\text{H5N5E2} + \text{Na}]^+$ of m/z 2504.914, $[\text{H6N5E2Am1} + \text{Na}]^+$ of m/z 2957.078 and $[\text{H7N6E2Am2} + \text{Na}]^+$ of m/z 3612.322. The .xy files generated by Flexanalysis were further processed with MassyTools [37]. A second round of internal spectral calibration was performed with at least 4 calibrants in the low m/z range and at least 3 calibrants in the medium m/z range, having to pass signal to noise ratio (S/N) at least above 15. The m/z window for calibration, peak

detection, and spectral data integration was taken at ± 0.45 Th. The background detection windows were set to 20 Th.

The MALDI-FT-ICR-MS spectra were acquired in serial mode. Thus, a single combined file was generated. This file was split into individual compound spectra and transformed into .xy files using DataAnalysis version 5 (Bruker Daltonics). Calibration of these spectra was performed in MassyTools, for which at least 4 calibrants in the low m/z range and at least 3 calibrants in the medium m/z range, have to pass S/N at least above 50. The m/z window for calibration was taken at ± 0.10 Th. Peak detection and spectral data integration was performed using an extraction window depending on the defined glycans in the analyte list. This was done so as to exclude interferences in the spectra. The background detection windows were set at the value of 20 Th.

The calibrant list and analyte list for MALDI-TOF-MS spectra and MALDI-FT-ICR-MS spectra are shown in Supplementary Tables S1 and S2, respectively. The table of all identified and quantitated glycans by MALDI-FT-ICR-MS and MALDI-TOF-MS, respectively, are shown in Supplementary Table S3. At least 85% of the theoretical isotopic distribution of each glycan analyte was integrated. The MassyTools output was used further for analyte curation, which was based on multiple criteria. These were $S/N \geq 9$, isotopic pattern quality ≤ 0.25 and mass accuracy between ± 20 ppm (MALDI-TOF-MS) or ± 10 ppm (MALDI-FT-ICR-MS). Spectra for which the number of glycan analytes passing these criteria were less than 50% of the total number of defined glycans in the analyte list, were not considered for further processing as these spectra were deemed of low quality. The absolute area of the curated glycans was corrected to 100% of their respective isotopic distribution, before using them in total area normalization.

Derived traits, focusing on features rather than individual glycans, were calculated from the relative areas of the glycan compositions using an in-house prepared R script (Supplementary Table S4). Statistical significance of the differences between pre-operative vs. post-operative colorectal cancer patient samples was assessed by a Wilcoxon matched-pairs signed-rank test with $\alpha=0.05$. Multiple-testing correction was performed using a false discovery rate of 1% calculated with the Benjamini and Hochberg method. These statistical tests were performed in GraphPad Prism version 8.0.1. The box and whisker plots used for representing the features were made by an in-house prepared R script.

Method optimization and assay performance

All optimization experiments of the assay were measured on the MALDI-TOF-MS (Supplementary Material `Assay optimization`). Data processing for these mentioned optimization experiments was done using the mass list of the negative control (fucosidase untreated TPNG) (Supplementary Table S2). Quantitation of residual core fucosylated glycans allowed the assessment of the completeness of the core defucosylation. Importantly, all identified antennary fucosylated glycans were also included in the mass list of the negative control (fucosidase untreated TPNG).

The intermediate precision of the antennary fucose assay for combined sample preparation and measurements on the MALDI-TOF-MS or MALDI-FT-ICR-MS were performed in three independent experiments on three different days within a period of 5 days. For each of these experiments, the assay was performed with nine replicates of glycan releases from a human plasma pool (Visucon-F, Affinity Biologicals). Data processing was performed as mentioned in the subsection 'Processing of MALDI-TOF-MS/MALDI-FT-ICR-MS data'.

Capillary electrophoresis - electrospray ionization mass spectrometry

Identification of core fucosylated glycans, antennary fucosylated glycans, and composition containing both isomers was done by comparing the MALDI-FT-ICR-MS spectra from the assay (core fucosidase treated) to the negative control (fucosidase untreated). The identified antennary fucosylated glycans and mixed fucosylated isomeric glycans were structurally confirmed by targeted collision induced dissociation (CID) fragmentation on a capillary electrophoresis - electrospray ionization – tandem MS (CE-ESI-MS/MS) platform. The samples were performed in 12 replicates of which nine were used for MALDI-FT-ICR-MS measurements while the remaining three were used for CE-ESI-MS/MS measurements (n=3).

For the CE-ESI-MS/MS measurement, the replicates from the assay and the negative controls were respectively pooled together and dried down in a vacuumed centrifuge (Salm en Kipp, Breukelen, Netherlands) at 50°C. They were used for permanent cationic labeling with GiRP as previously described [23] but with certain alterations. Briefly, 10 µL of GiRP labeling solution (7.5 mg GiRP dissolved in a solution of 720 µL ethanol and 80 µL glacial acetic acid) was added to the dried samples. The plate was sealed and mildly shaken on a plate shaker for 5 minutes before incubating at 60°C for 1 hour. After incubation, the samples were dried down in a vacuumed centrifuge at 50°C and then re-suspended in 5 µL of deionized water. In total, 3.6 µL of the GiRP labeled glycans were mixed with 2.4 µL of 250 mM ammonium acetate solution as leading electrolytes (250 mM ammonium acetate solution adjusted to pH 4 with glacial acetic acid) before being transferred into a vial (nanoVial, Sciex, Framingham, USA).

All CE-ESI-MS/MS analyses were performed on a static coated neutral capillary cartridge (Neutral OptiMS cartridge, Sciex), fitted into a CESI 8000 system (Sciex). The CE system was coupled with an Impact HD UHR-QTOF-MS system (Bruker Daltonics). When the capillary was not in use, a continuous flow of water at 10 psi was applied to the separation line. Prior to usage, the separation line and reverse line were filled with the background electrolyte containing 10% acetic acid (sonicated in a water bath for 10 minutes). Prior to sample injection, the separation line was flushed with 0.1 M HCl at a pressure of 100 psi for 5 minutes. This was followed by flushing the reverse line with background electrolyte at 75 psi for 3 minutes. The separation line was filled with background electrolyte by applying a pressure of 100 psi for 10 minutes. The sample was injected into the separation line of the capillary from the nanovials via a hydrodynamic injection of 12.5 psi for 24 seconds (about 5% of the capillary volume). The tip of the separation line was washed by momentary dipping it into a vial of background electrolyte, followed by injecting a background electrolyte plug with a pressure of 2.5 psi for 15 seconds. A 20 kV voltage of normal polarity (cathode toward the

end of the capillary) was applied on the capillary for 30 minutes. During this step, a continuous flow of 2 psi was applied only on the reverse line. After 30 minutes, a flow of background electrolyte is applied to both the separation line and reverse line by applying a pressure of 2 psi on both lines for 40 minutes. Finally, the voltage on the capillary was ramped down over 5 minutes to 1 kV before termination of the run. The capillary was maintained at 30°C throughout the analysis.

For the MS analysis, a dopant enriched nitrogen gas (acetonitrile as dopant) at 0.2 bar was used for nebulization at the ESI captive sprayer. The drying gas of nitrogen at 150°C was introduced at the source at 1.2 L/minute and the internal capillary of the MS was maintained at 1200 V. A targeted CID fragmentation was performed on 20 glycan analytes of interest. This list was divided into two inclusion lists on the software otof control version 3.4 (Build 14; Bruker Daltonics) which was used for operating the MS and MS/MS analysis. Hence each sample was measured twice in-order to fragment all the glycan analytes of interest. The MS/MS fragmentation spectra were collected at a rate of 1 Hz within an m/z -range of 150 - 2000 and at an absolute intensity threshold at 2274 on the m/z values of interest. The targeted precursor ions were isolated with a width of 8 – 15 Th depending on the m/z values. The collision energies of the CID cell was set in an m/z dependent manner, ranging from 35 eV for singly charged precursor ions of m/z 500 to 70 eV for singly charged precursor ions at m/z 2000. Data analysis was done using DataAnalysis version 5 (Bruker Daltonics).

Hydrophilic interaction liquid chromatography analysis

PNGase F released *N*-glycans from 12 replicates of human plasma samples (Visucon-F) were used for procainamide labeling and analysis on a HILIC-FLD-MSⁿ platform as previously described [38]. Following PNGase F treatment, 8 µL of each sample was dried down and the released *N*-glycans converted to aldoses with 0.1% formic acid, filtered through a protein binding plate (LC-PBM-96, Ludger, Oxford, UK), washed twice with 100 µL of water and dried. *N*-glycans were labeled by reductive amination in 10 µL of water and 10 µL procainamide labeling solution (LT-KPROC-24 containing NaCNBH₃, Ludger) and incubated at 65°C for 1 h. A HILIC-type clean-up plate (LC-PROC-96, Ludger) was used to remove unreacted procainamide dye. Procainamide labeled *N*-glycans were eluted in 300 µL of water. The samples were dried and resuspended in water (50 µL) for further analysis.

Procainamide-labeled samples were analyzed by HILIC-FLD-MSⁿ. 12.5 µL of each sample was injected into an ACQUITY BEH Glycan column (1.7 µm, 2.1x150 mm) at 40°C on a Dionex Ultimate 3000 UHPLC instrument with a fluorescence detector (ex = 310 nm and em = 370 nm attached to an Amazon Speed ETD (Bruker Daltonics). The running conditions used were as follows: solvent A was 50 mM ammonium formate (pH 4.4) (LS-NBUFFX40, Ludger), and solvent B was acetonitrile.

Gradient conditions were as follows: 0 to 53.5 min, 76 to 51% B, 0.4 mL/min; 53.5 to 55.5 min, 51% to 0% B, 0.4 mL/min to 0.2 mL/min; 55.5 to 57.5 min, 0% B at a flow rate of 0.2 mL/min; 57.5 to 59.5 min, 0 to 76% B, 0.2 mL/min; 59.5 to 65.5 min, 76% B, 0.2 mL/min; 65.5 to 66.5 min, 76% B, 0.2 mL/min to 0.4 mL/min; 66.5 to 70.0 min, 76% B, 0.4 mL/min. The Amazon

Speed settings used were as follows: source temperature, 250°C; gas flow, 10 L/min; capillary voltage, 4500 V; ICC target, 200,000; Max. accu. time (Maximum Accumulation Time), 50.00 ms; rolling average, 2; number of precursor ions selected, 3; release after 0.2 min; positive ion mode; scan mode, enhanced resolution; mass range scanned, 400 to 1500; target mass, 900.

Results and Discussions

The workflow for the antennary fucose assay is shown in Figure 2. Released *N*-glycans from human plasma were treated with an α 1,6-linkage-selective fucosidase (core fucosidase) to deplete core fucosylation. Antennary fucosylation remained and was relatively quantified by MALDI-FT-ICR-MS or MALDI-TOF-MS. Information on sialic linkage is obtained in parallel, potentially improving the estimation of sialyl-Lewis X abundance. An overview of all analytical methods used during the development of the assay is shown in Supplementary Figure S1.




Figure 2. Workflow of the antennary fucose assay for human plasma.

Human TPNG was $28.3\% \pm 0.5\%$ fucosylated. Most of this is core fucosylation (Supplementary Table S5). Hence, it was important to optimize the assay with a focus on a robust and complete depletion of core fucosylation of TPNG. This aids a robust relative quantitation of the remaining antennary fucosylated glycans by MALDI-MS. The efficient use of costly reagents, specifically the core fucosidase, was also addressed. During the optimization steps, completeness of core defucosylation was judged by the inability to quantify by MALDI-MS (signal to noise ratio (S/N) < 9) some of the most abundant core fucosylated glycans namely $[\text{H3N4F1} + \text{Na}]^+$ of m/z 1485.53 and $[\text{H4N4F1} + \text{Na}]^+$ of m/z 1647.59 (Supplementary Figure S4). Details pertaining to assay optimization are described in the Supplementary Material section 'Assay optimization'. For these optimized assay conditions, a complete core defucosylation of TPNG could already be achieved with 0.2 units of core fucosidase (Figure 3). However, to facilitate robustness of the core defucosylation a 2-fold greater amount (0.4 units) was chosen for further experiments. Equally important is the preservation of antennary fucosylation. A fucosidase specific, or at least highly selective, for the α 1,6-linkage over other linkages significant in TPNG (mainly α 1,3-linkage) is therefore essential. The MS/MS spectra provided in the Supplementary Material demonstrate that core fucoses are removed while antennary fucoses remain (see also following sub-section) with the chosen enzyme. The integrity of the antennary fucosylation under increased enzyme concentrations (Figure 3) and incubation times (data not shown) further supports the α 1,6-linkage selectivity. An absence of the oxonium ion of m/z 658.26 $[\text{galactose} - \text{N-acetylglucosamine}(\text{fucose})_2 + \text{H}]^+$ excluded a significant presence of Lewis Y or Lewis B structures.




Figure 3. Residual core fucosylation on TPNG after incubation with varying amounts of core fucosidase. The amounts of core fucosylation on complex *N*-glycans were calculated and were normalized to their lowest and highest mean values. Error bars show the standard deviation of the mean of three replicates.

Identification of antennary fucosylated glycans in total plasma *N*-glycome

Core fucosylated glycans and antennary fucosylated glycans in TPNG were identified by comparing the TPNG profile with and without core fucosidase treatment (Figure 4). A more detailed view can be found in Supplementary Figure S2 and Supplementary Figure S3 for MALDI-FT-ICR-MS and MALDI-TOF-MS spectra, respectively. Interestingly, some monofucosylated glycan compositions in TPNG showed a mixture of both core and antennary fucosylated isomers (Supplementary Figure S4). CID spectra, obtained on a CE-ESI-MS/MS platform, provided an orthogonal layer of evidence (Figure 5). CID spectra for all identified antennary fucosylated glycans are shown in Supplementary Figures S5 to S24. Antennary fucosylation was identified by the formation of the diagnostic B-ion of m/z 512.198 assigned as [galactose-*N*-acetylglucosamine(fucose)+H]⁺ [31]. Core fucosylation was identified by the formation of the Y-ion of m/z 501.219 assigned as [*N*-acetylglucosamine(fucose)-GiRP]⁺. Core fucosylation also generates, to a lesser extent, the B-ion of m/z 512.198 assigned as [mannose-*N*-acetylglucosamine(fucose)+H]⁺ caused by fucose rearrangement [30, 31, 34, 39]. This complicates the assessment of mixtures, especially relative quantitation by MS/MS. Although, fucose rearrangement also limits the sensitivity of antennary fucose identification in the presence of core fucose isomers, significant contributions of antennary fucose are still readily identified (Figure 5).




Figure 4. Identification of core fucosylated glycans and antennary fucosylated glycans by exoglycosidase and MALDI-FT-ICR-MS. The TPNG profile without core fucosidase treatment was compared to the profile after treatment, within **(A)** the m/z range of 1200 to 3200 and **(B)** the m/z range of 3120 to 4200. Core fucosylated glycans [red m/z values] are converted to their corresponding afucosylated glycans [purple m/z values], upon core fucosidase treatment. Only the antennary fucosylated glycans [blue m/z values] and the antennary fucose isomers of the mixed fucose isomeric (core or antennary fucosylation) glycans [green m/z values] remain after core fucosidase treatment. All m/z values of annotated glycans belong to $[M + Na]^+$ ions. The description of the glycan cartoons are shown in Figure 1.

Notably, no core fucosylation remained after core fucosidase treatment. This was assessed by the absence of the core fucosylated glycans H3N4F1 and H4N4F1 (S/N < 9) (Supplementary Figure S25). As expected, the corresponding afucosylated glycoforms increased in abundance (Figure 4). The remaining fucosylated glycans are suggested to be solely antennary fucosylated.

As similar relative abundances were maintained after core fucosidase treatment, the species, H6N5F2Am2E1, H6N5F1Am1E2, H7N6F1Am1E1, H7N6F1Am2E1, H7N6F1Am1E2, H7N6F1Am3E1, H7N6F2Am3E1, H7N6F1Am2E2, H7N6F2Am2E2, and H7N6F1Am1E3, are assigned as antennary fucosylated in human TPNG. This was confirmed by MS/MS (Supplementary Figure S14 to S23). Interestingly, we were able to prove that the difucosylated glycans, H6N5F2Am2E1, H7N6F2Am3E1 and H7N6F2Am2E2, contained only antennary fucosylation and no core fucosylation. Previously, these glycans have often been assigned as containing one core and one antennary fucose [22]. In fact, we were unable to identify any multifucosylated glycan compositions in TPNG having both core and antennary fucose residues on the same glycan. However, at low abundances (<0.5%), two such mixed, multifucosylated glycans, H6N5F2Am2E1 and H6N5F2Am1E2, have been convincingly demonstrated [23]. On haptoglobin, multifucosylated glycans having both core and antennary residues were shown to have clinical relevance in subtyping hepatocellular carcinoma patients [3]. Thus, it may be very important to differentiate between glycans with multiple antennary fucoses and glycans containing both a core and an antennary fucose. The former may be directly assessed with our assay, the latter indirectly, either via an increase of the resulting monofucosylated species or by comparison to the negative control (fucosidase untreated).

A range of monofucosylated compositions were found to be a mixture of core fucosylated and antennary fucosylated isomers, including for the following glycan compositions: H5N5F1, H5N4F1E1, H5N5F1E1, H5N4F1Am1E1, H5N4F1E2, H5N5F1E2, H6N5F1Am1E1, H6N5F1E2, and H6N5F1Am2E1. Their relative abundances were significantly lowered, but signals did not disappear after core fucosidase treatment (Supplementary Figure S4 and Table S4). These findings were further supported by their MS/MS spectra (Supplementary Figures S5 to S13). As a representative example, the MS/MS fragmentation of the monofucosylated composition H6N5F1E2 is shown without and with core defucosylation in Figures 5B and 5C, respectively. Fragmentation of this glycan from untreated human TPNG resulted in the formation of similar abundances of both a Y-ion of m/z 501.219 and a B-ion of m/z 512.198. This is typical of a mixture of core and antennary fucosylation (Figure 5B). Expectedly, the fragmentation of this glycan after core defucosylation, results in the formation of only the B-ion of m/z 512.198 which is indicative of only antennary fucosylation (Figure 5C). Thus, H6N5F1E2 in human TPNG is comprised of a mixture of core fucose isomers and antennary fucose isomers. Such monofucosylated glycan compositions which include mixtures of core fucose and antennary fucose isomers contribute to a total abundance of 12.1% \pm 1.0% in human TPNG. Our assay determined 3.1% \pm 0.3% of them to be antennary fucosylated (Supplementary Table S5).

A B-ion of m/z 831.325 was observed in several CID spectra which was tentatively assigned as $[N\text{-acetylneuraminic acid(amidated)-galactose-}N\text{-acetylglucosamine(fucose)+H}]^+$. This is an

unconventional motif because antenna fucosylation is generally observed on α 2,3 sialylated antennae. The ion may be caused by fucose rearrangement between the antennae [31]. For the composition H6N5F1E2 (Figure 5C), the higher abundance of the B-ion of m/z 512.198 compared to m/z 831.325, indeed indicates a Lewis X structure to be more likely. Additionally, for the compositions with only α 2,6 sialylated antennae, H5N4F1E2 and H5N5F1E2, we did not observe a B-ion of m/z 831.325 but rather the Y-ion of m/z 501.219 (Supplementary Figures S9B and S10B). Thus, these compositions are partly explained by incomplete core defucosylation. Their antennary fucosylated portion, suggested by the significant abundance of the Y-ion of m/z 512.198, could be due to side-products of the esterification of α (2-3) linked sialic acids [40-42].

After core fucosidase treatment, H6N5F2Am2E1 and H7N6F1Am1E2 showed a lower abundance (Supplementary Table S6). However, from the MS/MS spectra without fucosidase treatment, core fucosylation could not be confirmed on these glycans due to the lack of the Y-ion of m/z 501.219 (Supplementary Figures S16A and S18A). H6N5F2Am2E1 and H7N6F2Am2E1 both contribute to < 0.25% to TPNG, and the ratio of their abundances for core fucosidase treated / untreated is 0.83 and 0.88, respectively (Supplementary Table S5). Thus, if their core fucosylated isomers are present in TPNG, they might be too low abundant (\leq 0.03%) to be identified in MS/MS spectra of our CE-ESI-MS/MS platform. Furthermore, a complete depletion of core fucosylation for H5N5F1, H5N4F1E1, H5N5F1E1, H5N4F1E2 and H5N5F1E2 was not achieved as the Y-ion of m/z 501.219 was still observed in their MS/MS spectra, although the B-ion of m/z 512.198 is equally, if not more abundant (Supplementary Figures S5 to S7, S9 and S10). However, most of the core fucosylation was removed (Supplementary Figure S4). Due to the relatively low abundance of the affected glycans, this small overestimation is not likely to have a significant impact on the measurements. A pessimistic estimate is an 0.1% bias in relative quantitation of total antennary fucosylation (<3% for affected glycans, such as H5N4F1E1).




Figure 5. CE-ESI-MS/MS spectra of sialic acid derivatized and GiRP labeled TPNG for the confirmation of antennary, mixed isomeric (core or antennary fucosylation) and core fucosylated glycans. **(A)** The $[M+H]^{2+}$ ion of H4N4F1 (m/z 879.838) is fragmented for fucosidase untreated TPNG. Its fragment ions are indicative of core fucosylation. **(B)** The $[M+2H]^{3+}$ ion of H6N5F1E2 (m/z 975.709) [second isotope] is fragmented for fucosidase untreated TPNG. Its fragment ions are indicative of both core fucosylated and antennary fucosylated isomers. **(C)** The ion $[M+2H]^{3+}$ of H6N5F1E2 (m/z 975.709) [second isotope] is again fragmented, but for core fucosidase treated TPNG. Its fragmentation pattern is indicative of only antennary fucosylation. The descriptions of the glycan cartoons are shown in Figure 1. GiRP represents Girard's reagent P label; * represents an oxonium ion.

Assay performance

Intermediate precision was assessed by three independent experiments on different days each with nine replicates of glycan releases from a human plasma pool measured by MALDI-FT-ICR-MS. 70 glycans were quantified (Supplementary Table S7, Supplementary Figure S26), which included 19 antennary fucosylated glycans (Figure 6). These antennary fucosylated glycans make up $11.8\% \pm 0.9\%$ of total abundance in human TPNG, with the three most abundant antennary fucosylated glycans, H6N5F1Am1E2, H5N4F1Am1E1 and H6N5F1Am2E1, contributing $6.80\% \pm 0.63\%$, $0.84\% \pm 0.03\%$ and $0.66\% \pm 0.06\%$, respectively (Figure 6B). The abundance of H6N5F1Am1E2 is consistent with previous quantitation using MALDI-FT-ICR-MS [22]. The median of intermediate precisions for the 19 quantitated antennary fucosylated glycans is 12.4% (9.1% to 18.5% interquartile range; Supplementary Figure S27), which is in-line with the ca. 10% previously described for MALDI-FT-ICR-MS analysis of all TPNG glycans [22]. Notably, neither the focus on low abundant antennary fucosylated glycans (< 1%, except H6N5F1Am1E2) nor the additional processing steps resulted in a marked loss of precision.

Previous research quantified 21 antennary fucosylated glycans in human TPNG using a MALDI-FT-ICR-MS platform [22]. These antennary fucosylated glycans are consistent with our findings. However, we were also able to identify a mixture of both core fucose isomers and antennary fucose isomers for nine of these monofucosylated glycan compositions (Supplementary Figure S4). For example, we have identified H6N5F1E2 and H5N4F1Am1E1 as being a mixture of core fucose isomers and antennary fucose isomers. Previously, these glycans were assumed to be antennary fucosylated (H6N5F1E2) and core fucosylated (H5N4F1Am1E1), respectively. The specific measurement of antennary fucosylated glycans using our assay may increase the accuracy of the relative quantitation of antennary fucose.

To demonstrate the accuracy of the quantitation of antennary fucosylated glycans, procainamide labeled human TPNG was analyzed on a HILIC-FLD-MSⁿ platform [38]. This analytical platform was chosen for its accuracy and precision of measurements. Antennary fucosylated glycan peaks were identified from their CID spectra while relative quantitation was performed from the FLD chromatograms. By using the FLD chromatogram instead of the MS spectra for quantification, we overcome the ionization bias resulting from charge differences conferred by underivatized sialic acids (which applies to most antennary fucosylated glycans), as compared to the neutral glycans [43]. As the HILIC-FLD-MSⁿ platform did not identify antennary fucosylated tetraantennary glycans, we based the comparison to our MALDI-MS method on antennary fucosylation of triantennary glycans only. This includes nearly 70% of the total abundance of antennary fucosylated glycans in TPNG (Supplementary Table S7). With $32.4 \pm 1.1\%$ result from our MALDI-MS method were highly comparable results to the $34.7 \pm 1.3\%$ quantified with the HILIC-FLD-MSⁿ reference method. Thus, our assay is capable of accurately quantifying antennary fucosylation in TPNG.




Figure 6. Intermediate precision of sample preparation for assay and MALDI-FT-ICR-MS measurements of antennary fucosylated glycans in human TPNG. (A) The mean relative abundances of the 19 quantified antennary fucosylated glycans are shown with the error bars representing standard deviation ($n = 9$). **(B)** The relative standard deviations of the three most abundant antennary fucosylated glycans are shown. The description of the glycan cartoons are as described in Figure 1. [H = hexose, N = *N*-acetylhexosamine, F = deoxyhexose (fucose), Am = amidated *N*-acetylneuraminic acid ($\alpha 2,3$ -linked), E = ethyl esterified *N*-acetylneuraminic acid ($\alpha 2,6$ -linked)].

MALDI-FT-ICR-MS is not widely available. Therefore, we also demonstrated that the assay can be measured with a somewhat more widespread MALDI-TOF-MS instrument (Supplementary

Figure S28). In total, 58 glycans could be relatively quantitated of which 15 were antennary fucosylated glycans with a total abundance of $7.3\% \pm 0.7\%$ using MALDI-TOF-MS (Supplementary Table S8). In contrast, 19 antennary fucosylation glycans out of 70 glycans in total were quantified with a total abundance of $11.8\% \pm 0.9\%$ using MALDI-FT-ICR-MS (Supplementary Table S7). Thus, fewer antennary fucosylated glycans were quantified with MALDI-TOF-MS due to the expectedly lower sensitivity of the instrument. Furthermore, the differences in quantified antennary fucosylation between the instruments can be accounted for by the different efficiencies of ionization and ion transfer to the detector over the m/z range; the MALDI-FT-ICR-MS having been more efficiently tuned for good sensitivity in the high mass range. Consistent with the overall trend, the three most abundant antennary fucosylated glycans also show lower (or equal) values in the MALDI-TOF-MS, H6N5F1Am1E2, H5N4F1Am1E1, and H6N5F1Am2E1, contributing to $3.9\% \pm 0.4\%$, $0.81\% \pm 0.07\%$ and $0.41\% \pm 0.05\%$ of the total abundance, respectively (Supplementary Figure S28B). The abundance of H6N5F1Am1E2 is consistent with previous MALDI-TOF-MS analysis of TPNG [26, 27]. The median of intermediate precisions for the 15 quantitated antennary fucosylated glycans is 12.5% (10.6% to 13.6% interquartile range; Supplementary Figure S29), which is virtually identical to our MALDI-FT-ICR-MS measurements of the 19 antennary fucosylated glycans. The intermediate precision of all *N*-glycans quantitated by MALDI-TOF-MS is shown in Supplementary Figure S30. Thus, the assay measured on either instrument can be used for detailed quantitation of antennary fucosylation in human TPNG.

Quantitation of antennary fucosylation in colorectal cancer patient samples

To demonstrate the applicability of the developed antennary fucose assay and especially its ability to reveal clinically relevant markers of antennary fucosylation, total serum *N*-glycome (TSNG) samples were analyzed from colorectal cancer patients pre and post tumor resection. This is of specific interest, as colorectal cancer has been associated with an increase in antennary fucosylation and a decrease in core fucosylation, next to an increase in *N*-glycan antennarity and sialylation [6, 8]. Previously, TSNG has been analyzed by MALDI-TOF-MS on sample pairs (pre-operative vs. post-operative) of 61 colorectal cancer patients from the same cohort [8]. The derived traits that were a proxy for antennary fucosylation on *N*-glycans are especially relevant to our study. Multifucosylation on triantennary glycans and $\alpha 2,3$ -sialylation per antenna in fucosylated triantennary glycans were significantly lowered in the post-operative patient samples as compared to pre-operative samples [8]. The latter derived trait was used as a proxy for sialyl-Lewis X epitopes in TSNG. These changes were thought to be associated with the recovery of the patients since values were closer to healthy controls in the post-operative than in the pre-operative samples.




Figure 7. Alteration in features related to antennary fucosylated glycans for colorectal cancer patient samples. Derived traits for glycans were calculated to evaluate antennary fucosylation changes between the 14 pairs of pre-operative (Pre) vs. post-operative (Post) colorectal cancer patient samples. The patient samples were measured with the antennary fucose assay (MALDI-FT-ICR-MS readout). Significant changes were observed for antennary fucosylation in complex *N*-glycans (CFan), antennary fucosylation in triantennary glycans (A3Fan), antennary fucosylation in tetraantennary glycans (A4Fan), α 2,3-sialylation per antenna of total antennary fucosylated glycans (CFanAm), α 2,3-sialylation per antenna of diantennary antennary fucosylated glycans (A2FanAm), sialyl-Lewis X abundance (relative area%) in TPNG (SLeX), Lewis X abundance in TPNG (LeX) and the ratio of sialyl-Lewis X to Lewis X abundances in TPNG (SLeX / LeX). No significant changes were observed for antennary fucosylation in diantennary glycans (A2Fan), α 2,3-sialylation per antenna of triantennary antennary fucosylated glycans (A3FanAm) and α 2,3-sialylation per antenna of tetraantennary antennary fucosylated glycans (A4FanAm). The *p*-values shown are from a Wilcoxon matched-pairs signed-rank test with confidence level taken as 95%. Multiple-testing correction was performed using a false discovery rate of 1% calculated with the Benjamini and Hochberg method. The *p*-values < 0.0073 are considered significant and are represented with an asterisk (*).

The feasibility to analyze clinically relevant markers of antennary fucosylation with our assay was demonstrated on sample pairs (pre-operative vs. post-operative) of 14 colorectal cancer patients. Glycosylation changes in colorectal cancer patient samples are shown in Figure 7 and Supplementary Figure S31. Details on features and their calculations are shown in Supplementary Table S4. In line with previous findings, we were able to show that post-operative patient samples had a significantly lower total antennary fucosylation on total complex *N*-glycans (CFan) as compared to pre-operative samples (Figure 7). Unlike previously, no significant differences were observed in α 2,3-sialylation per antenna of antennary fucosylated triantennary glycans (A3FanAm), but rather a significantly lowered α 2,3-sialylation per antenna of antennary fucosylation diantennary glycans (A2FanAm) in post-operative patient samples as compared to pre-operative samples (Figure 7). Since we used only a quarter of the samples, compared to the previous study, missing statistical power provides a simple explanation for missing the sialylation effect on fucosylated triantennary glycans. However, when we focused on the quantitation of sialyl-Lewis X epitopes, it was possible to reproduce the finding. We are able to calculate highly specific derived traits based on antennary fucosylated glycans structures, allowing us to study more specific glycan features. For example, assuming α 2,6-sialylated antennae are not fucosylated, there is no preference for fucosylation of α 2,3-sialylated or asialylated antennae and multiple fucoses are on different arms, the relative abundances of sialyl-Lewis X can be calculated. This is indeed lowered in the post-operative samples (Figure 7). The discovery of a novel association with A2FanAm is also easily explained by the increased specificity of our assay. The trait is largely composed of compositions representing a mixture of core and antennary fucose isomers before core defucosylation. Hence, in a regular TPNG / TSNG MALDI-MS analysis unrelated variations in core fucosylation would interfere with the detection of changes in antennary fucosylation of diantennary glycans.

The changes in CFan are mainly contributed by the triantennary glycans (A3Fan) and tetraantennary glycans (A4Fan) rather than the diantennary glycans (A2Fan) and bisecting diantennary glycans (A2BFan) (A2BFan shown in Supplementary Figure S31). We did not observe a change in A2Fan and A2BFan. Without core defucosylation, these traits would largely measure core fucosylation (Supplementary Figure S4). Furthermore, we also observed a significantly lowered multiantennary fucosylation (CFm_an) in post-operative patient samples as compared to pre-operative samples (Supplementary Figure S31). Finally, we also approximated the abundance of glycans having Lewis X or sialyl-Lewis X epitopes in TPNG. sialyl-Lewis X / Lewis X ratio was significantly lowered in post-operative patient samples as compared to pre-operative samples. This change was mainly contributed by a decreased abundance of sialyl-Lewis X in post-operative samples, although the Lewis X abundance was also lowered. This may be associated with a decreased inflammatory state of the recovering patient [11, 12].

All studied features, except for Lewis X ($p = 0.0513$), were replicated for the MALDI-TOF-MS measurements of the samples (Supplementary Figure 32). Thus, MALDI-TOF-MS measurements are sufficient to detect many of the clinical changes.

Conclusion

We developed an assay for the relative quantitation of antennary fucosylation and approximation of Lewis X and sialyl-Lewis X abundances in TPNG, based on high-throughput MALDI-MS analysis. This assay is compatible with high sensitivity and ultrahigh-resolution MALDI-FT-ICR-MS or with MALDI-TOF-MS. In total, 19 antennary fucosylated glycans were relatively quantified with precision and accuracy expectable of a MALDI-MS approach. Furthermore, the assay was applied to measuring biomedically relevant changes in antennary fucosylation in colorectal cancer patients pre vs. post tumor resection. Next to previous findings that could be repeated, despite the reduced sample size, the increased specificity enabled the discovery of novel associations. Additionally, we were able to investigate more specialized features based on antennary fucosylation which would not be possible with regular TPNG analysis. The next steps would include further automatization of the assay and perform a high throughput analysis on a large set of patient samples.

Supplementary information

Supplementary tables and figures are available online free of charge via

<https://www.frontiersin.org/articles/10.3389/fchem.2020.00138/full#h11>

4

Acknowledgements

This research was supported by the European Union (GlySign, Grant No. 722095) and the NWO (Vernieuwingsimpuls Veni Project No. 722.016.008).

References

1. Blomme, B., et al., Alteration of protein glycosylation in liver diseases. *J Hepatol*, 2009. 50(3): p. 592-603.
2. Testa, R., et al., N-glycomic changes in serum proteins in type 2 diabetes mellitus correlate with complications and with metabolic syndrome parameters. *PLoS One*, 2015. 10(3): p. e0119983.
3. Zhu, J., et al., Analysis of serum haptoglobin fucosylation in hepatocellular carcinoma and liver cirrhosis of different etiologies. *J Proteome Res*, 2014. 13(6): p. 2986-97.
4. Benicky, J., et al., Quantification of fucosylated hemopexin and complement factor H in plasma of patients with liver disease. *Anal Chem*, 2014. 86(21): p. 10716-23.
5. Saldova, R., et al., Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. *Glycobiology*, 2007. 17(12): p. 1344-56.
6. Doherty, M., et al., Plasma N-glycans in colorectal cancer risk. *Sci Rep*, 2018. 8(1): p. 8655.
7. Holst, S., et al., N-glycosylation Profiling of Colorectal Cancer Cell Lines Reveals Association of Fucosylation with Differentiation and Caudal Type Homebox 1 (CDX1)/Villin mRNA Expression. *Mol Cell Proteomics*, 2016. 15(1): p. 124-40.
8. de Vroome, S.W., et al., Serum N-glycome alterations in colorectal cancer associate with survival. *Oncotarget*, 2018. 9(55): p. 30610-30623.
9. Juszczak, A., et al., Plasma Fucosylated Glycans and C-Reactive Protein as Biomarkers of HNF1A-MODY in Young Adult-Onset Nonautoimmune Diabetes. *Diabetes Care*, 2019. 42(1): p. 17-26.
10. Thanabalasingham, G., et al., Mutations in HNF1A result in marked alterations of plasma glycan profile. *Diabetes*, 2013. 62(4): p. 1329-37.
11. Higai, K., et al., Glycosylation of site-specific glycans of alpha1-acid glycoprotein and alterations in acute and chronic inflammation. *Biochim Biophys Acta*, 2005. 1725(1): p. 128-35.
12. Brinkman-van der Linden, E.C., et al., Inflammation-induced expression of sialyl LewisX is not restricted to alpha1-acid glycoprotein but also occurs to a lesser extent on alpha1-antichymotrypsin and haptoglobin. *Glycoconj J*, 1998. 15(2): p. 177-82.
13. Pivac, N., et al., Human plasma glycome in attention-deficit hyperactivity disorder and autism spectrum disorders. *Mol Cell Proteomics*, 2011. 10(1): p. M110.004200.
14. Thanabalasingham, G. and K.R. Owen, Diagnosis and management of maturity onset diabetes of the young (MODY). *Bmj*, 2011. 343: p. d6044.
15. Schober, E., et al., Phenotypical aspects of maturity-onset diabetes of the young (MODY diabetes) in comparison with Type 2 diabetes mellitus (T2DM) in children and adolescents: experience from a large multicentre database. *Diabet Med*, 2009. 26(5): p. 466-73.
16. Hattersley, A.T. and K.A. Patel, Precision diabetes: learning from monogenic diabetes. *Diabetologia*, 2017. 60(5): p. 769-777.
17. Lauc, G., et al., Genomics meets glycomics-the first GWAS study of human N-Glycome identifies HNF1alpha as a master regulator of plasma protein fucosylation. *PLoS Genet*, 2010. 6(12): p. e1001256.

18. Cserni, G., Nodal staging of colorectal carcinomas and sentinel nodes. *J Clin Pathol*, 2003. 56(5): p. 327-35.
19. Nairn, A.V., et al., Regulation of glycan structures in animal tissues: transcript profiling of glycan-related genes. *J Biol Chem*, 2008. 283(25): p. 17298-313.
20. Royle, L., et al., HPLC-based analysis of serum N-glycans on a 96-well plate platform with dedicated database software. *Anal Biochem*, 2008. 376(1): p. 1-12.
21. Stumpo, K.A. and V.N. Reinhold, The N-glycome of human plasma. *J Proteome Res*, 2010. 9(9): p. 4823-30.
22. Vreeker, G.C.M., et al., Automated Plasma Glycomics with Linkage-Specific Sialic Acid Esterification and Ultrahigh Resolution MS. *Anal Chem*, 2018. 90(20): p. 11955-11961.
23. Lageveen-Kammeijer, G.S.M., et al., Highly sensitive CE-ESI-MS analysis of N-glycans from complex biological samples. *Nat Commun*, 2019. 10(1): p. 2137.
24. Staudacher, E., et al., Fucose in N-glycans: from plant to man. *Biochim Biophys Acta*, 1999. 1473(1): p. 216-36.
25. Knezevic, A., et al., High throughput plasma N-glycome profiling using multiplexed labelling and UPLC with fluorescence detection. *Analyst*, 2011. 136(22): p. 4670-3.
26. Reiding, K.R., et al., High-throughput profiling of protein N-glycosylation by MALDI-TOF-MS employing linkage-specific sialic acid esterification. *Anal Chem*, 2014. 86(12): p. 5784-93.
27. Bladergroen, M.R., et al., Automation of High-Throughput Mass Spectrometry-Based Plasma N-Glycome Analysis with Linkage-Specific Sialic Acid Esterification. *J Proteome Res*, 2015. 14(9): p. 4080-6.
28. Vanderschaeghe, D., et al., High-throughput profiling of the serum N-glycome on capillary electrophoresis microfluidics systems: toward clinical implementation of GlycoHepatoTest. *Anal Chem*, 2010. 82(17): p. 7408-15.
29. Ruhaak, L.R., et al., Optimized workflow for preparation of APTS-labeled N-glycans allowing high-throughput analysis of human plasma glycomes using 48-channel multiplexed CGE-LIF. *J Proteome Res*, 2010. 9(12): p. 6655-64.
30. Chen, X. and G.C. Flynn, Analysis of N-glycans from recombinant immunoglobulin G by on-line reversed-phase high-performance liquid chromatography/mass spectrometry. *Anal Biochem*, 2007. 370(2): p. 147-61.
31. Wuhrer, M., A.M. Deelder, and Y.E. van der Burgt, Mass spectrometric glycan rearrangements. *Mass Spectrom Rev*, 2011. 30(4): p. 664-80.
32. Lattova, E., J. Skrickova, and Z. Zdrahal, Applicability of Phenylhydrazine Labeling for Structural Studies of Fucosylated N-Glycans. *Anal Chem*, 2019. 91(13): p. 7985-7990.
33. Banazadeh, A., et al., Characterization of glycan isomers using magnetic carbon nanoparticles as a MALDI co-matrix. *RSC Adv*, 2019. 9(35): p. 20137-20148.
34. Harvey, D.J., et al., "Internal residue loss": rearrangements occurring during the fragmentation of carbohydrates derivatized at the reducing terminus. *Anal Chem*, 2002. 74(4): p. 734-40.

35. Vanderschaeghe, D., et al., Endoglycosidase S Enables a Highly Simplified Clinical Chemistry Procedure for Direct Assessment of Serum IgG Undergalactosylation in Chronic Inflammatory Disease. *Mol Cell Proteomics*, 2018. 17(12): p. 2508-2517.
36. Selman, M.H., et al., Cotton HILIC SPE microtips for microscale purification and enrichment of glycans and glycopeptides. *Anal Chem*, 2011. 83(7): p. 2492-9.
37. Jansen, B.C., et al., MassyTools: A High-Throughput Targeted Data Processing Tool for Relative Quantitation and Quality Control Developed for Glycomic and Glycoproteomic MALDI-MS. *J Proteome Res*, 2015. 14(12): p. 5088-98.
38. Kozak, R.P., et al., Comparison of procainamide and 2-aminobenzamide labeling for profiling and identification of glycans by liquid chromatography with fluorescence detection coupled to electrospray ionization-mass spectrometry. *Anal Biochem*, 2015. 486: p. 38-40.
39. Lettow, M., et al., The role of the mobile proton in fucose migration. *Anal Bioanal Chem*, 2019. 411(19): p. 4637-4645.
40. Suzuki, N., T. Abe, and S. Natsuka, Quantitative LC-MS and MS/MS analysis of sialylated glycans modified by linkage-specific alkylamidation. *Anal Biochem*, 2019. 567: p. 117-127.
41. Toyoda, M., et al., Quantitative derivatization of sialic acids for the detection of sialoglycans by MALDI MS. *Anal Chem*, 2008. 80(13): p. 5211-8.
42. Pongracz, T., M. Wuhrer, and N. de Haan, Expanding the Reaction Space of Linkage-Specific Sialic Acid Derivatization. *Molecules*, 2019. 24(19): p. 3617.
43. Wheeler, S.F., P. Domann, and D.J. Harvey, Derivatization of sialic acids for stabilization in matrix-assisted laser desorption/ionization mass spectrometry and concomitant differentiation of alpha(2 --> 3)- and alpha(2 --> 6)-isomers. *Rapid Commun Mass Spectrom*, 2009. 23(2): p. 303-12.

